Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Ran Reshef, Jacques Azzi, Ernesto Ayala, Mohamad Cherry, Richard A. Nash, Marie Luise Hütter‐Krönke, Paolo Caimi, Bastian von Tresckow, Swathi Namburi, Francisco Pérez-Miralles, Armin Ghobadi, Valentín Ortiz-Maldonado
+14 more Breogan Rodriguez-Acevedo, Alisha Desai, Lisa M. Kelly, Alexis Melton, Burhan Chaudhry, Rafael Sarmiento, Lingyun Lyu, Griff McTume, Takafumi Ide, Praneeth Jarugula, Melissa J. Harnois, Jerill Thorpe, Ashley Kern Koegel, Fabian Müller
DOI: 10.1016/j.jtct.2025.12.014
Cited by: 2

Fields of Study & Subjects

CAR-T cell therapy research Cutaneous lymphoproliferative disorders research Biosimilars and Bioanalytical Methods

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
2
Pages
S1–S1
Publication date
1 February 2026
Language
EN